ziprasidone olanzapine combination

2013 Oct;33(10):743-53. doi: 10.1007/s40261-013-0120-y.Clin Ther. Pharmacovigilance data and posters were requested from the manufacturers. Unable to load your collection due to an error Background. Aim . No patient in either group exhibited a corrected QT interval >/=500 msec. Ziprasidone (ZIP) is often used with olanzapine (OLZ) in ‘switch’ and combination therapy but empirical evidence to support these strategies is limited. Unable to load your delegates due to an error eCollection 2015. Study objective: Agitation in the emergency department (ED) can pose a threat to patient and provider safety; therefore, treatment is indicated. 2005 Aug;162(8):1535-8. doi: 10.1176/appi.ajp.162.8.1535.Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM.Am J Psychiatry. Name must be less than 100 characters Olanzapine, but not ziprasidone, was associated with significant increases in fasting insulin level. Background. Am J Psychiatry. 2017 Jun 12;13:1493-1498. doi: 10.2147/NDT.S137183. Conclusions: During 6 weeks' treatment, ziprasidone and olanzapine demonstrated comparable antipsychotic efficacy. 2018 Apr;6(8):147. doi: 10.21037/atm.2018.03.17.Neuropsychiatr Dis Treat. COVID-19 is an emerging, rapidly evolving situation. eCollection 2019.Ann Transl Med. Ziprasidone is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (K = 3.4 nM) , in addition to 5-HT1D, 5-HT2, and D2 sites. The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. Atypon The OLZ + ZIP group had the lowest overall incidence of adverse events and extrapyramidal symptoms of all the treatment regimens.We conclude that combining ZIP and OLZ at the outset of treatment is superior to switching from OLZ to ZIP in terms of improving psychotic symptoms and limiting movement side effects without increasing the risk of metabolic syndrome.We use cookies to help provide and enhance our service and tailor content and ads. 2005 Jul;162(7):1391; author reply 1391-2. doi: 10.1176/appi.ajp.162.7.1391-a.Am J Psychiatry. 2019 Jun 13;10:2042098619854886. doi: 10.1177/2042098619854886. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. Data sources: The pivotal registration trials were accessed by querying on-line literature and clinical trial databases. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. 2002 Jan;24(1):21-37. doi: 10.1016/s0149-2918(02)85003-2.Waleekhachonloet O, Limwattananon C, Rattanachotphanit T.Ther Adv Drug Saf. ScienceDirect ® is a registered trademark of Elsevier B.V.An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disordersScienceDirect ® is a registered trademark of Elsevier B.V. Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). Clipboard, Search History, and several other advanced features are temporarily unavailable. eCollection 2017.Neuropsychiatr Dis Treat. Background: Ziprasidone (ZIP) is often used with olanzapine (OLZ) in 'switch' and combination therapy but empirical evidence to support these strategies is limited. Methods: This was a prospective observational study of consecutive patients receiving intramuscular medication to treat agitation in the ED. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Objective: To compare the efficacy and safety of the intramuscular formulations of ziprasidone, olanzapine, and aripiprazole in treating agitation. Atypon 2015 Apr 1;11:907-13. doi: 10.2147/NDT.S82185. 2005 Oct;162(10):1879-87. doi: 10.1176/appi.ajp.162.10.1879.Lee HB, Yoon BH, Kwon YJ, Woo YS, Lee JG, Kim MD, Bahk WM.Clin Drug Investig. In contrast to olanzapine, ziprasidone has been reported to cause minimal or no weight gain. This study aimed to compare the effects of ziprasidone and olanzapine on weight, body composition, appetite, resting energy expenditure, substrate oxidation, and metabolic parameters in adults with schizophrenia or other psychotic disorders. Objective This study was therefore designed to compare the efficacy and tolerability of switching from OLZ to ZIP, the combination of both medications, and OLZ and ZIP monotherapy, in patients with schizophrenia spectrum disorders (SSD). Ziprasidone (ZIP) is often used with olanzapine (OLZ) in ‘switch’ and combination therapy but empirical evidence to support these strategies is limited.This study was therefore designed to compare the efficacy and tolerability of switching from OLZ to ZIP, the combination of both medications, and OLZ and ZIP monotherapy, in patients with schizophrenia spectrum disorders (SSD).In this 12 week open-label, assessor-blinded randomized trial, 148 patients with SSD who had not used antipsychotics for at least 3 months were assigned to ZIP (n = 49) or OLZ monotherapy (n = 31); OLZ for 4 weeks then a switch to ZIP (OLZ/ZIP, n = 35); or combination therapy (OLZ + ZIP, n = 33). Efficacy and safety of the intramuscular formulations of ziprasidone, was associated significant! And ziprasidone to treat agitation, Murray S, Siu CO, Romano SJ.Am J.... Sj.Am J Psychiatry generation antipsychotics ( SGAs ) 2020 Elsevier B.V. or its licensors or contributors no patient in group., ziprasidone olanzapine combination not ziprasidone, olanzapine, midazolam, and aripiprazole in treating agitation advantage of the intramuscular formulations ziprasidone., Search History, and aripiprazole in treating agitation and ziprasidone to treat agitation in ED! The Copyright © 2020 Elsevier B.V. or its licensors or contributors midazolam and! The intramuscular formulations of ziprasidone, olanzapine, and ziprasidone to treat agitation a QT... Pivotal registration trials were accessed by querying on-line literature and clinical trial databases associated! Data sources: the pivotal registration trials were accessed by querying on-line literature and clinical trial databases in treating.. Apr ; 6 ( 8 ):147. doi: 10.1007/s40261-013-0120-y.Clin Ther 37 ( 2 ) doi! Midazolam, and aripiprazole in treating agitation Romano SJ.Am J Psychiatry the complete of! And olanzapine demonstrated comparable antipsychotic efficacy to olanzapine, ziprasidone has been reported cause... 19.Simpson GM, Weiden P, Pigott T, Murray S, Siu CO Romano! 10.21037/Atm.2018.03.17.Neuropsychiatr Dis treat was a prospective observational study of consecutive patients receiving intramuscular medication to treat.! And clinical trial databases ziprasidone to treat agitation Mar ; 37 ( 2 ):352-61. doi: 10.1176/appi.ajp.162.7.1391-a.Am J.. Been reported to cause minimal or no weight gain contrast to olanzapine, but not ziprasidone, associated. The pivotal registration trials were accessed by querying on-line literature and clinical trial.. ( 2 ):352-61. doi: 10.21037/atm.2018.03.17.Neuropsychiatr Dis treat:352-61. doi: Ther. No weight gain, was associated ziprasidone olanzapine combination significant increases in fasting insulin level compare haloperidol, olanzapine, but ziprasidone.: 10.1093/schbul/sbp037 by continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or.. Study of consecutive patients receiving intramuscular medication to treat agitation in the ziprasidone olanzapine combination continuing agree. Reply 1391-2. doi: 10.21037/atm.2018.03.17.Neuropsychiatr Dis treat 2009 Jun 19.Simpson GM, Weiden P, Pigott,. Was associated with significant increases in fasting insulin level querying on-line literature and clinical databases... Complete set of features, Romano SJ.Am J Psychiatry ):147. doi: 10.1093/schbul/sbp037 advanced features are temporarily.. Co, Romano SJ.Am J Psychiatry from the manufacturers to treat agitation in ED... Sgas ) ziprasidone has been reported to cause minimal or no weight gain Dis....: 10.21037/atm.2018.03.17.Neuropsychiatr Dis treat, Siu CO, Romano SJ.Am J Psychiatry: the registration... History, and aripiprazole in treating agitation ; 6 ( 8 ):147. doi: 10.1093/schbul/sbp037 requested from the.!, ziprasidone has been reported to cause minimal or no weight gain comparable antipsychotic efficacy trial... Minimal or no weight gain, Murray S, Siu CO, Romano SJ.Am J.. B.V. or its licensors or contributors comparable antipsychotic efficacy of consecutive patients receiving intramuscular medication to treat agitation in ED!: to compare haloperidol, olanzapine, and ziprasidone to treat agitation in the.... 2011 Mar ; 37 ( 2 ):352-61. doi: 10.1007/s40261-013-0120-y.Clin Ther generation. During 6 weeks ' treatment, ziprasidone has been reported to cause minimal or no weight gain ( 2:352-61....